Developed by discovered by D-Pharm, DP-VPA is a drug indicated for the treatment of patients who are suffering from epilepsy, migraine and bipolar disorder.
As per the terms of the agreement, NHWA is responsible to pay upfront and milestones payments to D-Pharm.
In addition, upon reaching defined annual sales NHWA will also pay annual sales bonuses and royalties on DP-VPA sales to to D-Pharm over a certain threshold in China.
NHWA will be responsible for development, manufacturing and commercialization of DP-VPA in China.
The development of DP-VPA in China will be performed in compliance with applicable FDA standards and will be a part of the global development effort.
D-Pharm and NHWA will also cooperate on development and optimization of the manufacturing process for DP-VPA.
D-Pharm CEO Alex Kozak said this is D-Pharm’s third licensing agreement with an Asian company.
"Importantly, the data generated by NHWA gives them the opportunity to accelerate global development of DP-VPA," Kozak said.